EUVIMEDEUVIMED entdecken
CrossrefInfokarte

New Serratane Triterpenoid and Musashi2 inhibitors from Huperzia serrata

Tamara Balsiger, Malik Rakhmanov, Alessandro Prescimone, Annalena Kaiser, Kim-Dung Huynh, Andreas Papassotiropoulos, Robin Teufel, Attila Stetak, Eliane Garo

Planta Medica · 2026-10-01 · 92 (13) · 1209-1218

DOI: 10.1055/a-2900-3049 ↗
AbstractBibliografische Angaben

Abstract

Abstract Forgetting and memory formation are 2 distinct processes, both essential for the survival of humans and other animals. The protein Musashi2 (MSI2) was recently discovered as a key regulator of forgetting in the model organism Caenorhabditis elegans, making it an attractive therapeutic target for drug discovery and development. Here, we report a fluorescence polarization assay-based screening campaign aimed at identifying MSI2 inhibitors from 2,844 plant extracts. The dichloromethane extract of the aerial parts of Huperzia serrata, a plant traditionally used in Chinese medicine for the treatment of memory dysfunction, was identified as a hit and subsequently subjected to HPLC-based activity profiling. Scale-up isolation identified fatty acids, namely linoleic acid (11) and palmitoleic acid (12), both eluting within the main active window. As other fractions also seem to display activity, although weaker, their minor constituents were also investigated, revealing 1 new serratane triterpenoid (1) and 7 known serratene triterpenoids 2-8, their biosynthetic precursor α-onocerin (9), as well as an abietane diterpene (10). The absolute configuration of compound 1 was established by X-ray crystallography. All isolated compounds were evaluated for their activity, revealing that linoleic acid (11) and palmitoleic acid (12) inhibited MSI2 with IC50 values of 14.6 and 23.1 µM, respectively, while compound 10 only showed moderate activity (IC50 of 34.4 µM).

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →